Global Autologous Cell Therapy Market By Source (Bone Marrow, Epidermis, Mesenchymal Stem Cells, Hematopoietic Stem Cells, and Chondrocytes), By Application (Cancer, Neurodegenerative Disorders, Cardiovascular Disorders, Autoimmune Disorders, Orthopedics, and Wound Healing), By End-User (Hospitals & Clinics, Ambulatory Centers, and Academics & Research), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

In 2022, the Global Autologous Cell Therapy Market accounted for USD 5.5 Billion and is expected to grow USD 33.1 Billion in 2032. Between 2023 and 2032, this market is estimated to register A CAGR of 20.2%.

Autologous cell therapy is a medical practice that uses the patient’s cells to repair or replace damaged or diseased tissue. This alternative therapy differs from allogeneic cell therapy, which utilizes cells from another donor. Autologous cell therapy has the potential to treat a range of diseases, such as heart disease, cancer, and autoimmune disorders.

Therapy usually entails harvesting cells from patients, such as stem cells or immune cells, and then cultivating or altering them in a laboratory before reinjecting them back into the patient’s body. One of the advantages of autologous cell therapy is that it minimizes the potential risk of rejection or other immune reactions that may arise with allogeneic cell therapy. Furthermore, since these cells come from within a patient’s body, there is no possibility of transmission of infections or diseases from a donor.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The market is driven by rising number of clinical trials and product approvals for autologous cell therapy.
• Bone marrow segment dominated the market with 44.2% share in 2022
• Cancer is the most common application because autologous cell therapy is considered as the most effective treatment alternative for vaious types of cancer.
• Other diseases that require autologous cell therapy include neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, and wound healing.
• Hospitals & clinics segment held the largest market share of 42.7% in 2022.
• North America dominated the market due to presence of key players and rising number of clinical trials in the US.
• Some of the key players include BrainStorm Cell Therapeutics, Bristol Myers Squibb, Holostem Terapie Avanzate S.R.L, Caladrius Biosciences Inc., Pharmicell Co. Inc, Opexa Therapeutics, U.S. Stem Cell Inc., Lonza Group AG, and Novartis.

Driving Factors

Technological Advancements and Approvals for Autologous Cell Therapy Drive the Market Growth of the Autologous Cell Therapy Market.

Autologous cell therapy can be an effective tool in tackling cancer by collecting & altering a patient’s immune cells (such as T cells) so they specifically find and destroy cancer cells. CAR-T therapy, also known as CAR-T therapy, has shown promising results in clinical trials & has been approved for use in certain types of blood cancers. Autologous cell therapy can also be employed to repair and regenerate damaged tissues like cartilage in joints or heart muscles. Autologous cell therapy has the potential to treat neurological disorders like Parkinson’s disease & spinal cord injury by collecting a patient’s stem cells and using them in the lab for creating new tissue which can then be transplanted and returned to the patient.

Autologous cell therapy has already shown good results in treating Parkinson’s disease & spinal cord injury. Autologous cell therapy is an approach that involves collecting a patient’s neural stem cells and using them to replace damaged or lost neurons in the brain or spinal cord. Autologous cell therapy can also be employed during cosmetic procedures like facelifts to improve skin quality and reduce signs of aging by collecting fat cells from within and filling in wrinkles and other facial lines.

The increasing number of clinical studies & the expanding use of cell treatments internationally are credited with driving the growth of the COVID-19 market. Research centers, biotech & pharmaceutical companies, as well as government agencies from different nations, are concentrating on quick and efficient diagnostic methods. The market is also anticipated to expand as a result of rising clinical studies for autologous cell treatments.

For example, clinical research was launched to address the population of Sweden, who had autologous hematopoietic stem cell transplantation from January 2020 to March 2021. Positive findings from this research may result in the creation of novel treatments for the condition. These promising reports can drive the growth of the autologous cell therapy market in the upcoming years.

Restraining Factors

High Capital Investment For Cell Therapy Plants, Lack of Skilled and Trained Workforce.

People searching for the most up-to-date alternative remedies for several illnesses have become more interested in stem cell therapy. Every day, new treatments are developed & people around the world are turning away from standard drug regimens & hospital visits in favor of these more cost-effective options.

Unfortunately, developing stem cell therapies remains incredibly costly; this presents a significant restraint for expanding the market. Autologous cell therapies require skilled persons to run the therapy. And the absence of a skilled and trained workforce can become a restraint for the autologous cell therapy market.

Growth Opportunities

Cancer Treatment and Cosmetic Applications are some Opportunities in Autologous Cell Therapy Market.

Autologous cell therapy can be used to treat cancer by collecting & modifying a patient’s immune cells like T cells to target & destroy cancer cells. This approach is known as CAR-T which has shown promising results in clinical trials & has been approved for use in some types of blood cancers. Autologous cell therapy is also used for repairing & regenerate damaged tissues, like cartilage in joints or heart muscle. This can be achieved by collecting a patient’s stem cells & using them to grow new tissue in the lab, which can then be transplanted back into the patient.

Autologous cell therapy has shown potential in the treatment of neurological disorders like Parkinson’s disease & spinal cord injury. This approach includes collecting a patient’s neural stem cells & using them to replace damaged or lost neurons in the brain or spinal cord. Autologous cell therapies can be used in cosmetics procedures, like facelifts, to improve skin quality & reduce the signs of aging. This is achieved by collecting a patient’s fat cells & using them to fill in wrinkles & other facial lines.

Trending Factors

Growing Demand for Personalized Medicine, Growing Popularity of Natural and Alternative Therapies are Some Recent Trends in Autologous Cell Therapy Market.

There are several recent trends in the autologous cell therapy market which include, the expiration of patents on biologic autologous Cell therapy has led to the development of biosimilars that have the potential to reduce the cost of infertility treatment and increase patient access to care. As genomics & molecular biology advance, personalized medicine is becoming an increasingly important area of research in infertility treatment. The development of drugs targeted to a specific patient’s genetic makeup could improve the effectiveness of infertility treatment and reduce adverse effects.

Patients are increasingly looking for non-invasive treatment options for infertility which has led to the development of new non-invasive therapies, like acupuncture and herbal medicine which are gaining popularity in the infertility treatment market. There is increasing interest in natural & alternative therapies for infertility, like dairy supplements and herbal remedies. This has led to the development of new natural and alternative products which are gaining popularity in the infertility treatment market.

Source Analysis

The Bone Marrow Accounted for the Largest Revenue Share in Autologous Cell Therapy Market in 2022.

Based on source, the market is segmented into bone marrow, epidermis, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, and other sources. Among these types, the bone marrow segment is expected to be the most lucrative segment in the global autologous cell therapy market, with the largest revenue share of 44.2% in 2022 and a projected CAGR of 21.8% during the forecast period.

Autologous cell therapy with bone marrow has proven successful in treating various diseases. It draws upon the patient’s stem cells that are extracted from either bone marrow or blood before treatment and stored for later use. Autologous cell therapy using bone marrow provides certain advantages over using donor stem cells.

The Mesenchymal Stem Cells Segment is Fastest Growing Source Segment in Autologous Cell Therapy Market.

The mesenchymal stem cells segment is projected as the fastest growing source segment in the autologous cell therapy market from 2023 to 2031. Owing to They have both preclinical and clinical applications in tissue regeneration as well as therapy for immune diseases. For example, Celltex Therapeutics Corporation recently announced that they have begun discussions with the FDA regarding a study using MSCs against COVID-19 symptoms. Furthermore, the company has researched the safety and efficiency of using MSCs for patients suffering from injuries, pain, and maladies associated with vascular, and autoimmune conditions as well as chronic obstructive pulmonary disease (COPD) or pneumonia.

Application Analysis

Cancer Segment Holds the Significant Share of Application Segment in Autologous Cell Therapy Market.

Based on application, the market is divided into cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, orthopedics, wound healing, and other applications. Among these, cancer is dominant in the application segment in the autologous cell therapy market, with a market share of 40.2% and a CAGR of 22.3. This is due to autologous cell therapy emerging as a promising treatment option for cancers such as leukemia, lymphoma, and solid tumors.

Autologous cell therapy involves extracting immune cells from patients which are then genetically modified and reinjected back into them to target and destroy cancer cells. This approach has seen remarkable success in clinical trials, leading to the approval of several autologous cell therapies used in cancer treatment.

Wound Healing Segment is Identified as Fastest Growing Application Segment in Projected Period.

Wound healing is also an important application segment in the autologous cell therapy market and it is expected to grow with a CAGR of 22.4%. In 2020 this segment accounted for a market share of 20.7.%. It is growing fast due to autologous cell therapy being an innovative treatment that uses patients’ skin cells to grow in a lab and apply to wounds in order to heal. This approach has shown great promise in treating chronic wounds such as diabetic foot ulcers, which can be difficult to heal with traditional methods.

End-User Analysis

The Hospitals & Clinics Accounted for the Largest Revenue Share in Autologous Cell Therapy Market in 2022.

Based on end-user, the market is segmented into hospitals & clinics, ambulatory centers, academics & research, and other end-users. Among these types, the hospitals & clinics segment is expected to be the most lucrative segment in the global autologous cell therapy market, with the largest revenue share of 42.7% in 2022 and a projected CAGR of 22.7% during the forecast period. Cardiovascular diseases, the increasing burden of cancer, and neurodegenerative disorders have led to increased requirements for treatment and therapies.

The Academics & Research Segment is Fastest Growing End-User Segment in Autologous Cell Therapy Market.

The academics & research segment is projected as the fastest growing end-user segment in the autologous cell therapy market with a market share of 28.7% in 2022. Interest in CAR T therapy is growing worldwide and further research is being done. It utilizes live cells to treat and prevent diseases. Academic research currently focuses on bone marrow, mesenchymal stem cells, hematopoietic stem cells, chondrocytes, and epidermis research. For instance, Allogenic Therapeutics recently mentioned a survey conducted among U.S. academic institutes specializing in CAR T administration which revealed 81% agreed that CAR T therapies have assisted with cancer management.

Key Market Segments

Based on Source

• Bone Marrow
• Epidermis
• Mesenchymal Stem Cells
• Hematopoietic Stem Cells
• Chondrocytes
• Other Sources

Based on Application

• Cancer
• Neurodegenerative Disorders
• Cardiovascular Disorders
• Autoimmune Disorders
• Orthopedics
• Wound Healing
• Other Applications

By End-User

• Hospitals & Clinics
• Ambulatory Centers
• Academics & Research
• Other End-Users

Regional Analysis

North America Accounted for the Largest Revenue Share in Autologous Cell Therapy Market in 2022.

North America is estimated to be the most lucrative market in the global autologous cell therapy market, with the largest market share of 40.6%, and is expected to register a CAGR of 21.8% during the forecast period. Over the past few years, this region has witnessed fierce competition due to major players such as BrainStorm Cell Therapeutics and Bristol Myers Squibb. The market for autologous cells therapy has seen new growth opportunities due to an aging population, numerous immunological advantages, and lower rejection risks’

APAC is Expected as Fastest Growing Region in Projected Period in Autologous Cell Therapy Market.

Asia Pacific is expected as the fastest growing region in the forecast period in the autologous cell therapy market with a CAGR of 22.4. Atara Biotherapeutics recently reported the results of phase 1 clinical study on progressive multiple sclerosis patients treated with their autologous EBV-specific T-cell immunotherapy. This finding underscores the rising burden of diseases, active research efforts in autologous cell therapies, an established biotechnology sector, growing healthcare facilities, and increased awareness about cell therapies.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

In the global pharmaceutical market, there are Tier-1, Tier-2, and local competitors. Tier 1 and tier 2 firms dominate due to their product differentiation, financial stability, and diverse regional presence. To maintain their position in the market, they invest in R & D as well as taking advantage of strategic growth opportunities. Recently Thermo Fisher Scientific unveiled their integrated commercial packaging and distribution services which enable faster therapies to reach patients across Europe and America.

Listed below are some of the most prominent autologous cell therapy market industry players.

Market Key Players

• BrainStorm Cell Therapeutics
• Holostem Terapie Avanzate S.R.L
• Pharmicell Co. Inc
• Opexa Therapeutics
• Caladrius Biosciences Inc.
• S. Stem Cell Inc.
• Lonza Group AG
• Bristol Myers Squibb
• Novartis
• Autolus therapeutics
• Tego Science
• Corning Inc.
• Bio Elpida
• Vericel Corporation
• Catalent Inc.
• Sartorius AG
• Other Key Players

Recent Developments

• In November 2022, Tessa Therapeutics Ltd., a clinical-stage cell treatment company developing net-gen treatments for cancerous hematological malignancies and solid tumors, recently announced that three abstracts from their autologous CD30 clinical trials have been accepted for presentation at this year’s American Society of Hematology 64th Annual Meeting.
• In April 2022, Aspen Neuroscience Inc. has launched the first-ever patient screening program. It worked with multiple clinical screening sites across the U.S. The Trial-Ready Cohort Study of Aspen Neuroscience Inc. is a preliminary step in filing an Investigational New Drug Application with the U.S. Food & Drug Administration (ANPD001 & Investigation of iPSC-derived cell replacement therapies for Parkinson’s diseases).
• In April 2022, TreeFrog Therapeutics has launched The Stem Cell SpaceShot Grant, according for USD 100,000 in research funding in the field of stem cell biology & regenerative medicine.

Report Scope